Health in EUR 64 indicators covering health for EUR. IndicatorLatest Year10-yr change Rank Total tetanus - number of reported cases 85 2025 down 30.9% 16th Pertussis - number of reported cases 52,021 2025 up 2.8% 6th Infant mortality rate (probability of dying between birth and age 1) 6.52 2024 down 21.8% 15th Under-five mortality rate 7.7 2024 down 22.4% 15th Maternal mortality ratio 11.16 2023 down 21.1% 12th Number of deaths among children ages 5 to 9 years 8,827 2024 down 6.1% 15th Mortality rate among children ages 5 to 9 years 0.7826 2024 down 10.0% 15th Number of deaths among adolescents 10,454 2024 up 10.6% 16th Proportion of population with primary reliance on polluting fuels and 7.6% 2023 down 3.2% 12th Population with primary reliance on polluting fuels and technologies 18.78 2023 down 6.8% 12th Population with primary reliance on clean fuels and technologies for 229.11 2023 down 3.4% 6th Proportion of population with primary reliance on fuels and 16.8% 2023 down 18.3% 12th Population with primary reliance on fuels and technologies for 14.95 2023 down 18.2% 12th Prevalence of diabetes, age-standardized 8.68 2022 up 22.6% 16th Prevalence of diabetes, crude 11.52 2022 up 30.1% 10th Diphtheria tetanus toxoid and pertussis first-dose (DTP1) 94.0% 2025 down 2.1% 3rd Diphtheria tetanus toxoid and pertussis third-dose (DTP3) 91.0% 2025 down 2.2% 3rd Measles-containing-vaccine first-dose (MCV1) immunization coverage 92.0% 2025 down 2.1% 4th New HIV infections 0.16 2025 down 5.9% 3rd BCG immunization coverage among 1-year-olds (%) 94.0% 2025 up 2.2% 2nd Mean total cholesterol, crude 5 2018 down 2.0% 1st Mean HDL cholesterol, crude 1.4 2018 unchanged 1st Mean total cholesterol, age-standardized 4.9 2018 down 2.0% 1st Stunting prevalence among children under 5 years of age (%) 4.6% 2024 down 25.8% 17th Stunting numbers among children under 5 years of age (millions) 2,305 2024 down 34.9% 18th Overweight prevalence among children under 5 years of age (%) 7.5% 2024 down 7.4% 7th Overweight numbers among children under 5 years of age (thousands) 3,812 2024 down 17.0% 18th Adolescent mortality rate 0.7731 2021 down 25.6% 12th Incidence of tuberculosis 22 2024 down 42.1% 15th Deaths due to tuberculosis among HIV-negative people 1.6 2024 down 56.8% 15th Domestic private health expenditure (PVT-D) as percentage of current 33.0% 2023 down 6.1% 13th Prevalence of HIV among adults aged 15 to 49 0.5% 2025 up 25.0% 4th Estimated number of people (all ages) living with HIV 3.10 million 2025 up 47.6% 8th Estimated antiretroviral therapy coverage among people living with HIV 67.0% 2025 up 45.7% 8th Hypertension: effective treatment coverage (controlled hypertension) 27.3% 2019 up 38.6% 4th Hypertension: diagnosis coverage among adults aged 30-79 with 66.1% 2019 up 8.0% 4th Hypertension among adults aged 30-79 years, prevalence 36.9 2019 down 7.8% 2nd Hypertension treatment coverage among adults aged 30-79 with 56.2% 2019 up 10.2% 4th Hypertension: diagnosis coverage among adults aged 30-79 with 68.7% 2019 up 8.9% 4th Hypertension among adults aged 30-79 years, prevalence, crude 41.6 2019 down 5.0% 1st Number of new HIV infections 150,000 2025 unchanged 6th Births attended by skilled health personnel 99.1% 2025 up 0.1% 1st Inactivated first-dose polio vaccine (IPV1) immunization coverage 94.0% 2025 up 14.6% 2nd Low birth weight number 796 2020 down 12.6% 18th Concentrations of fine particulate matter 10.53 2023 down 29.5% 17th Estimated number of MDR/RR-TB incident cases 55,000 2024 down 38.9% 8th Mean hemoglobin level of children aged 6-59 months 119 2019 unchanged 5th Number of deaths attributed to non-communicable diseases, by type of 2.09 million 2019 up 5.2% 6th Hepatitis B surface antigen (HBsAg) prevalence 0.1% 2024 unchanged 10th Prevalence of anaemia in children aged 6-59 months 20.3% 2019 down 1.5% 11th Number of children aged 6-59 months with anaemia 11,457 2019 up 3.6% 15th Estimated number of malaria cases 0 2024 down 100.0% 12th Number of reported cases of poliomyelitis by wild poliovirus 0 2023 — 4th Estimated number of children needing antiretroviral therapy based on 19,000 2025 down 20.8% 12th Estimated antiretroviral therapy coverage among children 84 2025 up 13.5% 1st HPV immunization coverage estimates among primary target cohort (9-14) 46.0% 2025 up 64.3% 4th Smear-positive tuberculosis treatment-success rate 66.0% 2011 down 10.8% 14th Number of indigenous P. falciparum malaria cases 0 2020 — 12th Number of suspected malaria cases 861,048 2020 down 51.9% 12th Number of malaria positive cases by microscopy 144 2020 down 39.5% 12th Page 1 of 2 Next →